Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

EQRx, Inc. - Common Stock (NQ: EQRX )

1.760 +0.070 (+4.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,306,833
Open 1.690
Bid (Size) 1.760 (3)
Ask (Size) 1.850 (3)
Prev. Close 1.690
Today's Range 1.690 - 1.880
52wk Range 1.580 - 6.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce
EQRx Inc (NASDAQ: EQRX) will lay off 170 people and incur non-recurring costs of approximately $45 - $55 million for wind down, termination,  
Via Benzinga

Performance

YTD
-29.32%
-29.32%
1 Month
+9.32%
+9.32%
3 Month
-22.12%
-22.12%
6 Month
-49.86%
-49.86%
1 Year
-68.35%
-68.35%

More News

Read More
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
From EQRx, Inc.
Via GlobeNewswire
Earnings Outlook For EQRx
Via Benzinga
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
From EQRx, Inc.
Via GlobeNewswire
Why EQRx Shares Dropped 28.62% on Thursday
Via The Motley Fool
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
From Robbins LLP
Via Business Wire
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
From EQRx, Inc.
Via GlobeNewswire
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From EQRx, Inc.
Via GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
From EQRx, Inc.
Via GlobeNewswire
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022
Via Benzinga
BP To Rally Around 22%? Plus This Analyst Predicts $47 For YETI
Via Benzinga
Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
From EQRx, Inc.
Via GlobeNewswire
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
From EQRx, Inc.
Via GlobeNewswire
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
From EQRx, Inc.
Via GlobeNewswire
Abbott Laboratories, M&T Bank And Some Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday
Via Benzinga
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks Mostly Lower As Dow Drops 30 Points
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.